Complete Response to Afatinib in Lung Adenocarcinoma of Epidermal Growth Factor Receptor Exon-19 Deletion Mutation and Disease Recurrence on Drug Discontinuation
Open accessResearch articleFirst published online December, 2018
Complete Response to Afatinib in Lung Adenocarcinoma of Epidermal Growth Factor Receptor Exon-19 Deletion Mutation and Disease Recurrence on Drug Discontinuation